Novo Nordisk A/SNVONYSE
Loading
Gross Profit Growth AcceleratingAccelerating
Percentile Rank92
3Y CAGR+42.9%
5Y CAGR+30.9%
Year-over-Year Change
Year-over-year gross profit growth rate
3Y CAGR
+42.9%/yr
vs +259.7%/yr prior
5Y CAGR
+30.9%/yr
Recent acceleration
Acceleration
-216.8pp
Decelerating
Percentile
P92
Near historical high
vs 5Y Ago
3.8x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 11.13% |
| Q3 2025 | -10.84% |
| Q2 2025 | -1.82% |
| Q1 2025 | -10.27% |
| Q4 2024 | 21.09% |
| Q3 2024 | 3.84% |
| Q2 2024 | 4.24% |
| Q1 2024 | -0.74% |
| Q4 2023 | 13.94% |
| Q3 2023 | 5.54% |
| Q2 2023 | 2.79% |
| Q1 2023 | 13.44% |
| Q4 2022 | 3.82% |
| Q3 2022 | 9.01% |
| Q2 2022 | 0.23% |
| Q1 2022 | 9.42% |
| Q4 2021 | 8.55% |
| Q3 2021 | 7.53% |
| Q2 2021 | -1.78% |
| Q1 2021 | 5.56% |
| Q4 2020 | 2.90% |
| Q3 2020 | 2.13% |
| Q2 2020 | -11.43% |
| Q1 2020 | 5.57% |
| Q4 2019 | 7.07% |
| Q3 2019 | 0.06% |
| Q2 2019 | 2.56% |
| Q1 2019 | -2.07% |
| Q4 2018 | 7.42% |
| Q3 2018 | 1.27% |
| Q2 2018 | 1.42% |
| Q1 2018 | -2.40% |
| Q4 2017 | 4.25% |
| Q3 2017 | -7.79% |
| Q2 2017 | 0.12% |
| Q1 2017 | -1.84% |
| Q4 2016 | 4.68% |
| Q3 2016 | 0.59% |
| Q2 2016 | 1.90% |
| Q1 2016 | -5.32% |